Financial issues nag Swissray as company seeks new financing

Article

Company must restate financial resultsFinancial issues continue to dog digital x-ray developer Swissray International. While the vendor last month scored a large cash infusion that will help the firm market digital x-ray systems, Swissray has

Company must restate financial results

Financial issues continue to dog digital x-ray developer Swissray International. While the vendor last month scored a large cash infusion that will help the firm market digital x-ray systems, Swissray has announced that it must restate its financial results for several recent periods due to accounting irregularities.

On the positive side, Swissray has landed a cash infusion of $5.5 million from London-based Rolcan Finance that marks the first step in the firm's medium-term financial planning, according to Ruedi Laupper, chairman of the New York City-based firm. Swissray announced in February that the company was restructuring to better focus on sales of digital x-ray products like its AddOn-Multi-System, which received 510(k) clearance in December (SCAN 1/21/98). The financing is designed to meet the company's working capital needs, according to the vendor.

In addition to the financing, Swissray has made several changes in its executive lineup and to its board of directors. The company is looking for a new CEO and CFO, and director Akbar Seddigh and director and secretary Daniel Wuersch have resigned from the company's board of directors to pursue other interests. The resignations will not affect the company's reorganization, said Erwin Zimmerli, director of the board.

Swissray did not state whether the departures were related to recent discoveries that may require the company to restate its financial results for fiscal 1997 (end-June) and the first quarter of fiscal 1998 (end-September). In a filing with the Securities and Exchange Commission on Feb. 23, Swissray said that the restatement may be necessary due to the accounting treatment in the statements for convertible debentures issued by the company, as well as for certain expenses that should have been classified in the company's 1997 results as ordinary expenses, but instead were classified as extraordinary expenses. Swissray in 1997 reported sales of $13.2 million and a net loss of $10.9 million. The revelations, as well as the departure of Swissray's CFO, have forced the company to postpone the filing of its results for the second quarter (end-December).

Finally, Swissray reported that a $30 million order for its digital x-ray equipment to a customer in South Korea may not occur due to economic problems in that country. Swissray management considers it doubtful that the order will be filled in the current calendar year, or at all, according to the company.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.